Please login to the form below

Immuno-oncology; bringing patients closer to treatment

What do the new immunotherapies in oncology mean for those stakeholders who need to understand and make decisions about treatment?
By offering a novel way in which to fight cancer through harnessing the patient’s own immune system, extending survival, reducing toxic side-effects, and offering the possibility of a functional cure; immunotherapies offer positive news for all stakeholders involved in the fight against cancer.

What do these scientific leaps mean for those stakeholders who need to understand and make decisions about immunotherapies? Even more importantly, what do immunotherapies mean for patients who face diagnosis of advanced cancers?

Senior Associate Consultants Frances Hendry and Zoe Bartley tackle these complex questions.

Multi-stakeholder immuno-oncology experience

Blue Latitude Health has worked across a number of immunotherapies in melanoma, lung cancer, myeloma and acute lymphoblastic leukaemia. Our work to date has focused on primary research with Nurses, Oncologists, Pulmonologists, Haematologists, Pharmacists and Payers. With the insights generated from this research, we have developed a greater understanding of our stakeholders within immuno-oncology, their evolving challenges, and the impact those challenges have on patient outcomes. 

Immunotherapies for a lucky few; are your stars aligned?

Immuno-oncology (IO) is such an exciting area, especially for a patient. There’s been significant media coverage on the development of IO, on the so-called “super-patients,” and the possible outcomes that can be achieved; predominantly the potential of significant increases in overall survival (OS) coupled with manageable side-effects; something of a novelty for patients receiving cancer treatment. For these outcomes to become a reality, all the relevant parties need to work together, removing barriers to ensure that this is not an outlook restricted to a lucky few. What do these lucky few currently look like? And how can they become the majority? 

To begin with, the lucky few must have a type of cancer for which immunotherapies are currently indicated. Immunotherapies can treat head, neck, lung, prostate, renal, multiple myeloma, AML, ALL and kidney cancer. However, having one of these types of cancers does not present a guarantee that patients can be treated with one of these transformative products, instead it is only a very niche patient population that qualifies for their use and even then, predicting who will respond to treatments remains a key challenge.

The physician treating the patient, and the hospital in which they are based have a significant impact on availability of immunotherapies. What happens if a patient doesn’t live close to a central hospital that has access to the drug? Or worse still, where their physician doesn’t yet have a full working knowledge of the drug? Will such a physician stray from their regular working practices and advocate that a new form of therapy be secured on hospital formulary?  


Download the full article from Blue Latitude Health

18th August 2016

Share

Tags

Company Details

Blue Latitude Health

+44 203 328 1840

Contact Website

Address:
Blue Latitude Health
Crusader House
145-157 St John Street
London
EC1V 4QJ
United Kingdom

Latest content on this profile

The Challenges Of UX In Healthcare: Technology To Change Lives
Blue Latitude Health Director and Head of Customer Experience Elisa Del Galdo explores the latest digital healthcare trends and reveals the innovations changing the sector today.
Blue Latitude Health
Medical information in precision medicine
Global Medical Information Leader James Oughton reveals the top trends in medical information and precision medicine.
Blue Latitude Health
Behavioural insights to navigate complex healthcare markets
Blue Latitude Health Head of Insight Martine Leroy reveals how her team uses behavioural insights to help develop strong pharma brands and services, which successfully navigate complex situations.
Blue Latitude Health
Biotech: it's a people business
Nancy Hunter is the Marketing Director at a cutting-edge pharmaceutical company. Here she explains how a sharp focus on patients’ needs is driving a new operating model for marketing first-in-class drugs, and she describes how her mother’s experience as a cancer patient has shaped her own outlook on healthcare.
Blue Latitude Health
Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges and opportunities while introducing the latest issue of 'Perspective' magazine on this weighty topic.
Blue Latitude Health
Personas: a top tool for personalising pharma marketing campaigns
Healthcare customers are calling for greater personalisation in care from providers. Here, we explain why personas are the top tool for ensuring your brand meets this need efficiently and effectively.
Blue Latitude Health